Traders Purchase High Volume of Call Options on Insmed (NASDAQ:INSM)

Posted by Brian Himes on Oct 13th, 2026

Insmed, Inc. (NASDAQ:INSM – Get Free Report) was the target of unusually large options trading activity on Tuesday. Stock investors bought 8,177 call options on the company. This represents an increase of 206% compared to the typical daily volume of 2,676 call options.

Insider Transactions at Insmed

In other news, Director David Brennan sold 25,000 shares of the firm’s stock in a transaction that occurred on Wednesday, September 9th. The shares were sold at an average price of $124.00, for a total transaction of $3,100,000.00. Following the transaction, the director directly owned 39,238 shares of the company’s stock, valued at approximately $4,865,512. This trade represents a 38.92% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, COO Roger Adsett sold 239,850 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $133.27, for a total transaction of $31,964,809.50. Following the transaction, the chief operating officer directly owned 98,744 shares in the company, valued at approximately $13,159,612.88. This trade represents a 70.84% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 2.10% of the stock is owned by corporate insiders.

Institutional Trading of Insmed

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Reflection Asset Management bought a new position in shares of Insmed in the 4th quarter worth $30,000. CX Institutional purchased a new stake in shares of Insmed during the 3rd quarter worth $46,000. Whittier Trust Co. of Nevada Inc. boosted its position in Insmed by 86.6% during the first quarter. Whittier Trust Co. of Nevada Inc. now owns 444 shares of the biopharmaceutical company’s stock valued at $73,000 after purchasing an additional 206 shares in the last quarter. Harbor Investment Advisory LLC bought a new stake in Insmed during the second quarter valued at about $52,000. Finally, Versant Capital Management Inc raised its holdings in Insmed by 118.9% in the third quarter. Versant Capital Management Inc now owns 648 shares of the biopharmaceutical company’s stock worth $74,000 after purchasing an additional 352 shares in the last quarter.

Insmed Stock Down 0.6%

Shares of INSM traded down $0.57 during mid-day trading on Tuesday, hitting $97.98. The company’s stock had a trading volume of 774,479 shares, compared to its average volume of 2,923,074. The company’s 50-day moving average is $120.20 and its 200-day moving average is $119.46. Insmed has a 52-week low of $90.39 and a 52-week high of $212.75. The firm has a market capitalization of $21.40 billion, a price-to-earnings ratio of -23.88 and a beta of 0.83. The company has a current ratio of 3.72, a quick ratio of 3.40 and a debt-to-equity ratio of 0.74.

Insmed (NASDAQ:INSM – Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.67) by $0.61. The company had revenue of $425.49 million for the quarter, compared to analyst estimates of $395.50 million. Insmed had a negative net margin of 76.94% and a negative return on equity of 123.94%. Insmed’s revenue was up 296.1% compared to the same quarter last year. During the same period last year, the company posted ($1.70) earnings per share. On average, equities research analysts forecast that Insmed will post -1.84 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the company. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $235.00 target price on shares of Insmed in a research report on Tuesday, July 28th. Evercore reissued an “outperform” rating and set a $170.00 price target on shares of Insmed in a research report on Friday, August 7th. Morgan Stanley reissued an “overweight” rating and set a $218.00 price target on shares of Insmed in a research report on Friday, August 7th. Wolfe Research lowered Insmed from an “outperform” rating to a “peer perform” rating in a research note on Monday. Finally, Wells Fargo & Company lifted their price objective on Insmed from $161.00 to $169.00 and gave the company an “overweight” rating in a report on Friday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $200.30.

View Our Latest Stock Analysis on INSM

Insmed Company Profile

(Get Free Report)

Insmed Incorporated is a global biopharmaceutical company focused on developing and commercializing therapies for patients with serious and rare diseases. The company’s research and development activities center on pulmonary and inflammatory conditions, with an emphasis on diseases that have limited treatment options.

Insmed’s principal commercial product is ARIKAYCE liposomal, an inhaled formulation of amikacin used with a combination antibacterial regimen to treat refractory Mycobacterium avium complex lung disease in certain adult patients.